Agilent Technologies (NYSE:A) Price Target Cut to $126.00 by Analysts at Evercore ISI

Agilent Technologies (NYSE:A – Get Rating) had its price target decreased by Evercore ISI from $150.00 to $126.00 in a research report report published on Wednesday morning, The Fly reports. Evercore ISI currently has an outperform rating on the medical research company’s stock.

Several other brokerages have also weighed in on A. Credit Suisse Group cut their price objective on shares of Agilent Technologies from $170.00 to $160.00 and set an outperform rating on the stock in a research report on Wednesday. Barclays lowered their price target on Agilent Technologies from $140.00 to $135.00 and set an equal weight rating on the stock in a report on Wednesday. Citigroup lowered their price target on Agilent Technologies from $150.00 to $130.00 and set a neutral rating on the stock in a report on Wednesday. Robert W. Baird lowered their price target on Agilent Technologies from $174.00 to $144.00 and set an outperform rating on the stock in a report on Wednesday. Finally, Stifel Nicolaus dropped their target price on shares of Agilent Technologies from $153.00 to $135.00 and set a hold rating on the stock in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $151.35.

Agilent Technologies Stock Performance

Shares of A opened at $120.99 on Wednesday. Agilent Technologies has a one year low of $112.52 and a one year high of $160.26. The company has a 50-day moving average of $133.87 and a two-hundred day moving average of $144.11. The stock has a market cap of $35.78 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 1.89 and a beta of 1.03. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.11 and a quick ratio of 1.53.

Agilent Technologies (NYSE:A – Get Rating) last posted its quarterly earnings results on Tuesday, May 23rd. The medical research company reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.01. The business had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.09% and a return on equity of 30.35%. The firm’s revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.13 earnings per share. On average, equities research analysts expect that Agilent Technologies will post 5.68 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 26th. Investors of record on Monday, July 3rd will be paid a $0.225 dividend. The ex-dividend date is Friday, June 30th. This represents a $0.90 dividend on an annualized basis and a yield of 0.74%. Agilent Technologies’s payout ratio is currently 20.32%.

Hedge Funds Weigh In On Agilent Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Natixis Investment Managers International lifted its position in shares of Agilent Technologies by 2.0% in the 4th quarter. Natixis Investment Managers International now owns 3,245 shares of the medical research company’s stock worth $486,000 after purchasing an additional 65 shares during the period. Pinnacle Associates Ltd. increased its stake in Agilent Technologies by 1.1% during the 4th quarter. Pinnacle Associates Ltd. now owns 5,965 shares of the medical research company’s stock valued at $893,000 after purchasing an additional 67 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its stake in Agilent Technologies by 8.8% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 837 shares of the medical research company’s stock valued at $125,000 after purchasing an additional 68 shares in the last quarter. First Command Financial Services Inc. increased its stake in Agilent Technologies by 19.4% during the 1st quarter. First Command Financial Services Inc. now owns 461 shares of the medical research company’s stock valued at $64,000 after purchasing an additional 75 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Agilent Technologies by 34.8% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 298 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 77 shares in the last quarter.

About Agilent Technologies

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.